GPNMB CAR-T Cells Clear Glioblastoma in 6 of 7 Mice by Hitting Tumor and Myeloid Cells
Updated
Updated · Nature.com · Jul 1
GPNMB CAR-T Cells Clear Glioblastoma in 6 of 7 Mice by Hitting Tumor and Myeloid Cells
2 articles · Updated · Nature.com · Jul 1
Summary
Two intracranial doses of anti-GPNMB CAR-T cells completely cleared established glioblastoma in orthotopic mouse models, with durable control beyond 160 days in 6 of 7 GBM8 mice and beyond 120 days in 6 of 6 GBM4 mice.
GPNMB emerged as a shared target on malignant glioblastoma cells and immunosuppressive myeloid cells, while being largely absent from healthy adult brain, addressing a key reason CAR-T responses in glioblastoma often fade.
The engineered cells killed GPNMB-positive patient-derived tumor lines in vitro, lost potency against GPNMB-knockout targets, and also eliminated immunoregulatory macrophages without weakening tumor-cell killing.
In humanized and syngeneic glioma models, the therapy reduced tumor burden, prolonged survival past 100 days in immunocompetent mice, and removed both GPNMB-positive tumor cells and GPNMB-positive macrophages in brain tissue.
Glioblastoma remains nearly uniformly fatal, with median survival under 15 months and frequent recurrence, making the study a preclinical proof of a dual tumor-microenvironment targeting strategy rather than a clinical result.
This therapy attacks the tumor's own support system. Could this revolutionary approach inadvertently damage the healthy brain?
An AI found this brain cancer's weakness. Is this the key to a single therapy for many different cancers?
GPNMB CAR-T Therapy Achieves 86% Complete Tumor Clearance in Preclinical Glioblastoma Models: A New Hope for Dual-Target Immunotherapy
Overview
A major breakthrough in glioblastoma treatment has been achieved with the preclinical success of GPNMB-targeted CAR-T cell therapy. This innovative approach, published in July 2026, showed that engineered T-cells could effectively clear tumors in mouse models, with 6 out of 7 mice achieving complete tumor clearance. GPNMB stands out as a promising dual target because of its unique role in both tumor cells and the immune environment that protects them. This development marks a significant milestone, offering new hope for more precise and effective therapies against this aggressive brain cancer.